atorvastatin has been researched along with cyclic gmp in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, DC; Dogra, GK; Stanton, K; Watts, GF | 1 |
| Bem, AF; Metzger, IF; Nagassaki, S; Rocha, JB; Sertório, JT; Tanus-Santos, JE | 1 |
| Caracchini, R; Gresele, P; Guglielmini, G; Guzzetta, M; Impagnatiello, F; Momi, S; Monopoli, A; Olivieri, R | 1 |
| Aubin, MC; Carrier, M; Forcillo, J; Maltais, S; Perrault, LP; Shi, YF; Tardif, JC | 1 |
| Cunha, MP; Dal-Cim, T; Ludka, FK; Rodrigues, AL; Tasca, CI; Zeni, AL; Zomkowski, AD | 1 |
| Gross, PL; Ni, R; Peleg, T | 1 |
| Gerlach, RF; Guimaraes, DA; Meschiari, CA; Pinheiro, LC; Tanus-Santos, JE | 1 |
2 trial(s) available for atorvastatin and cyclic gmp
| Article | Year |
|---|---|
Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria.
Topics: Adolescent; Adult; Aged; Albuminuria; Apolipoproteins B; Atorvastatin; Brachial Artery; Cholesterol, LDL; Cross-Over Studies; Cyclic GMP; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Nitroglycerin; Pyrroles; Regional Blood Flow; Statistics, Nonparametric; Vasodilation; Vasodilator Agents | 2005 |
eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite.
Topics: Adolescent; Adult; Amino Acid Substitution; Atorvastatin; Cyclic GMP; Heptanoic Acids; Humans; Male; Malondialdehyde; Middle Aged; Nitric Oxide Synthase Type III; Nitrites; Polymorphism, Genetic; Pyrroles; Thiobarbiturates | 2006 |
5 other study(ies) available for atorvastatin and cyclic gmp
| Article | Year |
|---|---|
NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Aorta, Thoracic; Atorvastatin; Blood Pressure; Cell Line; Cholesterol; Cyclic GMP; Fibrinolytic Agents; Heptanoic Acids; Hyperlipidemias; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Knockout; Myocytes, Smooth Muscle; Nitric Oxide Donors; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Nitrites; PC12 Cells; Pulmonary Embolism; Pyrroles; Rabbits; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; Vasodilator Agents | 2007 |
Atorvastatin worsens left ventricular diastolic dysfunction and endothelial dysfunction of epicardial coronary arteries in normocholesterolemic porcine with left ventricular hypertrophy.
Topics: Angiotensin II; Animals; Aorta; Atorvastatin; Coronary Vessels; Cyclic GMP; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Echocardiography; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Nitrates; Nitrites; Pyrroles; Random Allocation; Swine; Vasodilation; Ventricular Dysfunction, Left | 2011 |
Acute atorvastatin treatment exerts antidepressant-like effect in mice via the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway and increases BDNF levels.
Topics: Animals; Antidepressive Agents; Arginine; Atorvastatin; Brain-Derived Neurotrophic Factor; Cyclic GMP; Depression; Heptanoic Acids; Male; Mice; Nitric Oxide; Pyrroles; Signal Transduction | 2013 |
Atorvastatin delays murine platelet activation in vivo even in the absence of endothelial NO synthase.
Topics: Administration, Oral; Animals; Atorvastatin; Blood Platelets; Cyclic GMP; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Membrane Glycoprotein IIb; Pyrroles; Receptors, Thrombin; Signal Transduction; Thrombin; Time Factors | 2012 |
Sodium nitrite attenuates MMP-9 production by endothelial cells and may explain similar effects of atorvastatin.
Topics: Atorvastatin; Cells, Cultured; Cyclic GMP; Dose-Response Relationship, Drug; Down-Regulation; Human Umbilical Vein Endothelial Cells; Humans; Matrix Metalloproteinase 9; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Phosphorylation; Signal Transduction; Sildenafil Citrate; Sodium Nitrite; Tetradecanoylphorbol Acetate; Transcription Factor RelA | 2016 |